These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 22673318)

  • 21. Changes within the thyroid axis after long-term TSH-suppressive levothyroxine therapy.
    Verburg FA; Smit JW; Grelle I; Visser TJ; Peeters RP; Reiners C
    Clin Endocrinol (Oxf); 2012 Apr; 76(4):577-81. PubMed ID: 22017394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical inertia in thyrotropin suppressive therapy for low-risk differentiated thyroid cancer: A real-world experience at an endocrine center in Bangkok.
    Thewjitcharoen Y; Chatchomchuan W; Wanothayaroj E; Butadej S; Nakasatien S; Krittiyawong S; Rajatanavin R; Himathongkam T
    Medicine (Baltimore); 2024 May; 103(21):e38290. PubMed ID: 38788029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association Between Thyroid Dysfunction and Incidence of Atrial Fibrillation in Patients With Hypertrophic Obstructive Cardiomyopathy.
    Meng X; Wang XL; Zhang ZY; Zhang K; Gao J; Zheng JL; Wang JJ; Liu YP; Yang J; Li C; Zheng YT; Shao C; Wang WY; Tang YD
    Front Endocrinol (Lausanne); 2022; 13():875003. PubMed ID: 35860698
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Suppressive thyroxine therapy of differentiated thyroid cancer in daily practice of a large cancer centre].
    Puch Z; Roskosz J; Jurecka-Lubieniecka B; Kula D
    Endokrynol Pol; 2006; 57 Suppl A():59-64. PubMed ID: 17091458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Evaluation of TSH suppression using a 3d-generation TSH assay: diagnostic and therapeutic consequences].
    Exer P; Staub JJ; Zulewski H; Müller B; Kunz M; Huber P
    Schweiz Med Wochenschr; 1992 Dec; 122(51-52):1964-7. PubMed ID: 1475661
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-Normal Thyroid-Stimulating Hormone Shows a Potential Causal Association With Arrhythmia Recurrence After Catheter Ablation of Atrial Fibrillation.
    Morishima I; Okumura K; Morita Y; Kanzaki Y; Takagi K; Yoshida R; Nagai H; Ikai Y; Furui K; Yoshioka N; Tsuboi H; Murohara T
    J Am Heart Assoc; 2018 Jul; 7(14):. PubMed ID: 30005553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with levothyroxine: beneficial effect of beta-blockade.
    Fazio S; Biondi B; Carella C; Sabatini D; Cittadini A; Panza N; Lombardi G; Saccà L
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2222-6. PubMed ID: 7608283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry.
    Cooper DS; Specker B; Ho M; Sperling M; Ladenson PW; Ross DS; Ain KB; Bigos ST; Brierley JD; Haugen BR; Klein I; Robbins J; Sherman SI; Taylor T; Maxon HR
    Thyroid; 1998 Sep; 8(9):737-44. PubMed ID: 9777742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased Risk of Atrial Fibrillation After Treatment for Differentiated Thyroid Carcinoma.
    Klein Hesselink EN; Lefrandt JD; Schuurmans EP; Burgerhof JG; Groen B; Gansevoort RT; van der Horst-Schrivers AN; Dullaart RP; Van Gelder IC; Brouwers AH; Rienstra M; Links TP
    J Clin Endocrinol Metab; 2015 Dec; 100(12):4563-9. PubMed ID: 26480284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effects of thyrotropin-suppressive therapy in patients with well-differentiated thyroid carcinoma].
    Miyakawa M
    Nihon Rinsho; 2007 Nov; 65(11):2073-7. PubMed ID: 18018573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Age-based factors modulating the required thyroxine dose to achieve thyrotropin suppression in intermediate-and high-risk papillary thyroid cancer.
    Zhou RY; Li N; Tan HL; Tang N; Chen P; Liu M; Ou-Yang DJ; Qin ZE; Ai L; Wei B; Zhao YX; Chang S; Huang P
    Front Endocrinol (Lausanne); 2023; 14():1126592. PubMed ID: 37388210
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thyroid Hormone Suppression Therapy.
    Biondi B; Cooper DS
    Endocrinol Metab Clin North Am; 2019 Mar; 48(1):227-237. PubMed ID: 30717904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early detection of isolated left ventricular diastolic dysfunction in high-risk differentiated thyroid carcinoma patients on TSH-suppressive therapy.
    Taillard V; Sardinoux M; Oudot C; Fesler P; Rugale C; Raingeard I; Renard E; Ribstein J; du Cailar G
    Clin Endocrinol (Oxf); 2011 Nov; 75(5):709-14. PubMed ID: 21645022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduced insulin sensitivity in differentiated thyroid cancer patients with suppressed TSH.
    De Melo TG; Souza AL; Ficher E; Fernandes AM; Montali Da Assumpção LV; Monte Alegre S; Zantut-Wittmann DE
    Endocr Res; 2018 May; 43(2):73-79. PubMed ID: 29083246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thyroid-stimulating hormone suppression for protection against hypothyroidism due to craniospinal irradiation for childhood medulloblastoma/primitive neuroectodermal tumor.
    Massimino M; Gandola L; Collini P; Seregni E; Marchianò A; Serra A; Pignoli E; Spreafico F; Pallotti F; Terenziani M; Biassoni V; Bombardieri E; Fossati-Bellani F
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):404-10. PubMed ID: 17601681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Delayed TSH recovery after dose adjustment during TSH-suppressive levothyroxine therapy of thyroid cancer.
    Kim HI; Kim TH; Kim H; Kim YN; Jang HW; Kim JH; Hur KY; Chung JH; Kim SW
    Clin Endocrinol (Oxf); 2017 Sep; 87(3):286-291. PubMed ID: 28375573
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thyrotropin versus thyroid hormone in regulating bone density and turnover in premenopausal women.
    Baqi L; Payer J; Killinger Z; Hruzikova P; Cierny D; Susienkova K; Langer P
    Endocr Regul; 2010 Apr; 44(2):57-63. PubMed ID: 20429634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Suppressive doses of thyroxine do not accelerate age-related bone loss in late postmenopausal women.
    Fujiyama K; Kiriyama T; Ito M; Kimura H; Ashizawa K; Tsuruta M; Nagayama Y; Villadolid MC; Yokoyama N; Nagataki S
    Thyroid; 1995 Feb; 5(1):13-7. PubMed ID: 7787427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validation of a decision rule for selective TSH screening in atrial fibrillation.
    Bellew SD; Moman R; Lohse CM; Hess EP; Bellolio MF
    West J Emerg Med; 2015 Jan; 16(1):195-202. PubMed ID: 25671041
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thyroid Hormone Therapy and Incident Stroke.
    Papaleontiou M; Levine DA; Reyes-Gastelum D; Hawley ST; Banerjee M; Haymart MR
    J Clin Endocrinol Metab; 2021 Sep; 106(10):e3890-e3900. PubMed ID: 34137866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.